5 Best Non-REIT Dividend Stocks To Buy

3. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 58 

Dividend Yield as of November 4: 3.64%

Gilead Sciences, Inc. (NASDAQ:GILD) is a California-based biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs in the United States, Europe, and internationally. On October 27, Gilead Sciences, Inc. (NASDAQ:GILD) posted a Q3 non-GAAP EPS of $1.90, beating market estimates by $0.47. The revenue of $7.04 billion topped Street consensus by $910 million. The company also raised its full-year 2022 sales outlook. With a dividend yield of 3.64% as of November 4, Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best dividend stocks to consider. 

On October 31, Maxim analyst Jason McCarthy raised the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $92 from $84 and kept a Buy rating on the shares. The company’s Q3 results were “strong”, supported by its Veklury and HIV franchise, the analyst wrote in a research note. He added that the more significant takeaway from Gilead Sciences, Inc. (NASDAQ:GILD)’s results was the ongoing growth in its oncology platform, with Trodelvy and Yescarta expanding penetration into current indications.

According to Insider Monkey’s second quarter database, 58 hedge funds were long Gilead Sciences, Inc. (NASDAQ:GILD), compared to 68 funds in the prior quarter. Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital is the biggest stakeholder of the company, with 15.6 million shares worth $968.45 million. 

Here is what ClearBridge Investments Sustainability Leaders Strategy has to say about Gilead Sciences, Inc. (NASDAQ:GILD) in its Q4 2021 investor letter:

“Other pharma companies are providing solutions as well. Biopharmaceutical company Gilead Sciences’ remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication administered by intravenous infusion; it can shorten the time to recovery in hospitalized patients and reduce the risk of hospitalization and death in non-hospitalized patients.”